Mach One Corporation

December 20, 2006 10:21 ET

Mach One's Immunogam'TM' Product Well Received at National Bovine and Equine Exhibitions

BELGIUM, WISCONSIN--(CCNMatthews - Dec. 20, 2006) - Mach One Corporation (PINK SHEETS:MNCN) through its wholly-owned subsidiary Vdx, Inc. recently attended the World Dairy Expo in Madison, Wisconsin and the 52nd Annual Convention of the American Association of Equine Practitioners in San Antonio, Texas as a major exhibitor.

VDx was on-hand at both events to showcase its Immunogam™ colostrums replacement product for both the dairy and equine industries. Immunogam™ was well received at both shows by both dairy owners and equine specialists.

Commenting on the events, Monte Tobin, President of VDx, Inc. stated, "It was really a pleasure to be able to roll out the newest edition of our Immunogam™ product to the dairy industry at the show in Madison, Wisconsin. Dairy farmers from all over the world showed great interest and excitement about the product and I believe that most, if not all, understood exactly what using Immunogam™ in their herds will mean to the overall increased health and production of their herds going forward." Tobin added, "Newborns are very susceptible to infection immediately after birth and are normally provided protection by mother's first milk or colostrums, which is rich in antibodies. This mechanism of protection is commonly referred to as Passive Transfer of Antibodies and is the primary means of defense until the offspring's own immune system produces sufficient levels of antibodies required for protection. Calves or foals that do not receive antibodies or receive insufficient levels, (a condition known as Failure of Passive Transfer FPT) in the first 24 hours after birth, are at high risk of infection and possible death due to failure of passive transfer of antibodies. Immunogam™ has been designed to provide the antibodies critical for the health and survival of these animals."

About Mach One Corporation:

Through its wholly-owned subsidiary VDx, Inc. (, the company specializes in Immune or Gamma Globulin testing (IgG) for the equine and bovine markets. VDx currently manufactures and sells specialized tests for bovine IgG, NEFA for the dairy industry, Equine IgG, and a failure of passive transfer test (FPT). FPT occurs in newborn foals and calves when antibodies are transferred in insufficient amounts from the mother's colostrums (More commonly called "Mother's First Milk"). Immunogam™ is a colostrums replacement, supplement and prophylactic, in sterile powder form, and can be administered orally or intravenously. VDx is also further developing a proprietary procedure to allow for large scale manufacturing of colostral replacement products for market along with an added ingredient for mastitis and Johnnes disease.

The IgG replacement market is estimated at 1.1 billion dollars per year.

Cautionary Statement: This news release may include certain "Forward-looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.

Contact Information

  • Cold Creek Capital Corporation
    Patrick Morrison
    Investor Relations
    (604) 649-1385